Recently, Lu Pengqi, Deputy Commissioner of the China National Intellectual Property Administration (CNIPA), met in Beijing with Severin Schwan, Chairman of the Board of Directors of the Roche Holding Ltd.

Lu stated that in recent years, intellectual property (IP) protection, as a key component of the business environment, has increasingly attracted the attention of both Chinese and foreign enterprises. The CNIPA has consistently upheld the principle of equal treatment and protection for IP of both domestic and foreign enterprises, effectively protecting the legitimate interests of foreign investors. Looking ahead, the CNIPA will continue to embrace a proactive and open approach and maintain good communication with rights holders and stakeholders from around the world.

Schwan noted that IP is the core competitiveness for innovative pharmaceutical enterprises to survive and grow. With China's continuously improving IP protection system, more and more multinational pharmaceutical enterprises are gaining confidence in the Chinese market and strengthening their localized strategic planning. Roche will continue to expand its R&D investment in China and actively promote pharmaceutical innovations originating from China to benefit the whole world.(Translated from CNIPA Website Chinese Version)